Bonus Biogroup seeks approval to market its drug to Corona patients - real or gimmick? The company's management explains that given the expected increase in the number of patients in critical condition, its drug is the only one that has succeeded in a Phase 2 clinical trial to prove a reduction in pneumonia in critically ill patients and shortened the hospitalization time.
News 
Market Data 
Discover 
